Targeted agents in cancer

Non-cytotoxic systemic treatments are a major component of systemic anti-cancer treatment. Targeted therapies are used to treat multiple tumour sites in both potentially curative and palliative settings and can be used in combination with chemotherapy, surgery and radiotherapy. Agents may have speci...

Full description

Saved in:
Bibliographic Details
Published inMedicine (Abingdon. 1995, UK ed.) Vol. 48; no. 2; pp. 108 - 112
Main Authors Ocen, Joanita, Kumar, Satish
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.02.2020
Subjects
Biomarker
molecular target
monoclonal antibodies
MRCP
personalized therapy
small molecules
Biomarker
MRCP
molecular target
small molecules
monoclonal antibodies
personalized therapy
Online AccessGet full text

Cover

More Information
Summary:Non-cytotoxic systemic treatments are a major component of systemic anti-cancer treatment. Targeted therapies are used to treat multiple tumour sites in both potentially curative and palliative settings and can be used in combination with chemotherapy, surgery and radiotherapy. Agents may have specific or multiple targets inhibiting cellular proliferation and cell growth and inducing cellular arrest and apoptosis. Patients must be closely observed on treatment; side effects can be class- or agent-specific. Despite high activity levels, cancer cells eventually develop mechanisms of resistance against targeted therapy.
ISSN:1357-3039
1878-9390
DOI:10.1016/j.mpmed.2019.11.008